FluoGuide (FLOU) Q1 2025 earnings summary

Executive summary

• Enrolled first patient in phase II trial (CT-005) for head and neck cancer, marking a key clinical milestone.

• Regulatory approval received for CT-005 trial; strong progress in partnerships and workflow integration.

• Focus remains on advancing FG001 for brain and head and neck cancers, with additional preclinical and partnership activities.

• Cash preparedness at DKK 36.5 million at Q1 2025 end supports 2025 milestones.

Financial highlights

• No revenue in Q1 2025, consistent with prior periods.

• Net loss of DKK 8,856 thousand in Q1 2025, compared to DKK 7,521 thousand in Q1 2024.

• Cash and bank position at DKK 20,982 thousand as of March 31, 2025, up from DKK 10,683 thousand a year earlier.

• Solvency ratio improved to 45% from 29% year-over-year.

• Result per share at DKK -0.65, slightly lower than DKK -0.62 in Q1 2024.

Outlook and guidance

• 2025 focus on advancing FG001 for high-grade glioma and head and neck cancer toward market approval.

• Key milestones: FDA consultation, interim data from CT-005, and new strategic partnerships.

• Long-term goal: first approval of FG001 in the USA and expansion into additional solid tumor indications.